Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

Waidmann, O.Abou-Alfa, G. K.Meyer, T.Cheng, A-LEl-Khoueiry, A. B.Rimassa, L.Ryoo, B-Y2024-06-122024-06-1220182296-52702296-5262https://hdl.handle.net/20.500.14551/26825[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trialConference Object41254254Q4WOS:000446816500618